AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
Live webcast presentation on Wednesday, April 3rd at 1:35 PM ET
美國東部時間4月3日星期三下午 1:35 的網絡直播演示
OCALA, Fla., March 28, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM ImmunoTech, will present at the MedInvest Biotech & Pharma Investor Conference being held in New York, N.Y., on Wednesday, April 3, 2024, at 1:35 PM ET.
佛羅里達州奧卡拉,2024 年 3 月 28 日 — AIM ImmunoTech公司 紐約證券交易所美國股票代碼:AIM)(“AIM” 或 “公司”)今天宣佈, Thomas K. Equels,JD 女士,首席執行官 AIM ImmunoTech 的,將出席 MedInvest 生物技術和製藥投資者會議 將於美國東部時間2024年4月3日星期三下午 1:35 在紐約州紐約舉行。
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, please visit the conference website.
除演講外,管理層還可以與註冊參加會議的合格投資者社區成員進行一對一的會議。有關該活動的更多信息,請訪問 會議網站。
A live webcast of the presentation will be available on the Events page of Investors section of the Company's website (www.aimimmuno.com).
A 網絡直播 演示文稿將在 活動 的頁面 投資者 公司網站的部分(www.aimmuno.com)。
About AIM ImmunoTech Inc.
關於 AIM ImmunoTech Inc
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
AIM ImmunoTech Inc. 是一家免疫製藥公司,專注於研究和開發治療多種癌症、免疫疾病和病毒性疾病(包括 COVID-19)的療法。該公司的主導產品是一種名爲Ampligen的同類首創研究藥物 (rintatolimod),一種dsRNA和高度選擇性的TLR3激動劑免疫調節劑,在全球重要的癌症、病毒性疾病和免疫系統疾病的臨床試驗中具有廣譜活性。
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
欲了解更多信息,請訪問 amimmuni.com 並通過以下方式與公司聯繫 X, 領英,以及 Facebook。
Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com
投資者聯繫人:JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com
譯文內容由第三人軟體翻譯。